Evidence map›Paper›PMID 37688622›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2024

Potential of oligonucleotide- and protein/peptide-based therapeutics in the management of toxicant/stressor-induced diseases.

Issa Sadeghian, Mina Akbarpour, Fatemeh Mohammad Alizadeh Chafjiri, Pegah Mohammad Alizadeh Chafjiri, Reza Heidari, Mohammad Hossein Morowvat, Razieh Sadeghian, Mohammad Javad Raee, Manica Negahdaripour

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Issa SadeghianPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mina AkbarpourAhvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Fatemeh Mohammad Alizadeh ChafjiriDepartment of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Pegah Mohammad Alizadeh ChafjiriSchool of Public Health, Boston University, Boston, MA, USA.
Reza HeidariPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Hossein MorowvatPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Razieh SadeghianAhvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Mohammad Javad RaeeCenter for Nanotechnology in Drug Delivery, Shiraz University of Medical Sciences, Shiraz, Iran.
Manica NegahdaripourPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. negahdaripour@sums.ac.ir.
Shiraz University of Medical Sciences · IRAhvaz Jundishapur University of Medical Sciences · IRBoston University · USHarvard University · US

Funding

Shiraz University of Medical Sciences, Iran, Islamic Republic Of 27128
6 · The paper itself

Abstract

Exposure to toxicants/stressors has been linked to the development of many human diseases. They could affect various cellular components, such as DNA, proteins, lipids, and non-coding RNAs (ncRNA), thereby triggering various cellular pathways, particularly oxidative stress, inflammatory responses, and apoptosis, which can contribute to pathophysiological states. Accordingly, modulation of these pathways has been the focus of numerous investigations for managing related diseases. The involvement of various ncRNAs, such as small interfering RNA (siRNA), microRNAs (miRNA), and long non-coding RNAs (lncRNA), as well as various proteins and peptides in mediating these pathways, provides many target sites for pharmaceutical intervention. In this regard, various oligonucleotide- and protein/peptide-based therapies have been developed to treat toxicity-induced diseases, which have shown promising results in vitro and in vivo. This comprehensive review provides information about various aspects of toxicity-related diseases including their causing factors, main underlying mechanisms and intermediates, and their roles in pathophysiological states. Particularly, it highlights the principles and mechanisms of oligonucleotide- and protein/peptide-based therapies in the treatment of toxicity-related diseases. Furthermore, various issues of oligonucleotides and proteins/peptides for clinical usage and potential solutions are discussed.

Indexed as

MicroRNAsOligonucleotidesHumansPeptidesRNA, Small InterferingRNA, UntranslatedMicroRNAsOligonucleotidesPeptidesRNA, Small InterferingRNA, UntranslatedmiRNAOligonucleotidePeptideProteinsiRNAToxicity

Identifiers

PMID37688622
OpenAlexW4386574694

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.